Clinical trials
Pancreatic Carcinoma clinical trials
Below are recruiting pancreatic carcinoma clinical trials, each written for real people, not researchers. We’re tracking 148 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06910657RecruitingPhase 1
IDOV-Immune vaccine for advanced solid tumors
This trial tests an experimental virus-based treatment for people with advanced solid tumors that have stopped responding to standard therapies. The treatment is designed to infect and destroy cancer cells while boosting the immune system.
St Louis, MissouriAges 18 years+ - NCT06753136Recruiting
Electrochemotherapy for internal organ tumors
This trial tests a treatment called electrochemotherapy for tumors in internal organs (like the liver or pancreas) when standard treatments are no longer possible. It uses a drug called bleomycin plus electric pulses to target cancer cells.
PadovaAges 18–99 - NCT06400472RecruitingPhase 1
Study of LY4170156 for advanced solid tumors
This study tests a new drug called LY4170156 for people with certain advanced solid tumors. It aims to see if the drug is safe and how well it works.
Scottsdale, ArizonaAges 18 years+ - NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07106827RecruitingPhase 1
Study of a new drug for advanced or resistant solid tumors
This trial tests a new drug, GV20-0251, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and helpful.
Chengdu, SichuanAges 18 years+ - NCT07454642RecruitingPhase 1
AVA6103 for advanced FAP-positive solid tumors
This trial tests a new drug called AVA6103 for certain advanced cancers that show a protein called FAP. It is for people who have already tried other treatments or cannot take them, and aims to see if the drug is safe and helps shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT06202066RecruitingPhase 2
Temozolomide plus Survivin Vaccine for Growing Neuroendocrine Tumors
This trial tests a combination of a chemotherapy drug (temozolomide) and a vaccine (SurVaxM) that targets a protein called survivin found in some neuroendocrine tumors. It is for patients whose tumors have grown after at least one prior treatment, with the goal of slowing or stopping further growth.
Buffalo, New YorkAges 18 years+ - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Gilbert, ArizonaAges 18 years+ - NCT03050268Recruiting
Study of childhood cancer risk in families
This study looks at inherited (family) risk for childhood cancers, including families with early cancers or known cancer risk conditions. It may help researchers understand why some children get cancer and improve future risk detection and care.
Memphis, TennesseeAges Any age - NCT06717295Recruiting
Blood test to find cancer early and track treatment
This study uses a blood test that looks at your platelets and immune cells to find common cancers early, and for certain cancers, to monitor how well treatment is working.
RosarioAges 40–75 - NCT05799274RecruitingPhase 1
Safety study of a new PET imaging drug for cancers
This Phase 1 study tests how safe RAD301 is and how it behaves in the body when given for PET imaging in healthy volunteers and people with certain cancers. It may help doctors learn whether this imaging drug can clearly show cancer areas and be tolerated well.
Princeton, New JerseyAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07557225Recruiting
New PET Scan for Detecting Multiple Cancer Types
This study tests a new type of PET scan (a specialized imaging test) that may better detect certain cancers by looking for a specific marker found on many tumor types. The scan uses a new tracer called 18F-T2 to help doctors see cancer more clearly.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT05714124Recruiting
Testing liver procedures to treat tumors when surgery isn’t possible
This trial studies different ways to place treatments inside the liver to control liver tumors when they can’t be removed with surgery or ablation. It may help certain people by improving how well the tumor is treated while keeping liver function safer.
MilanAges 18 years+ - NCT06337084RecruitingPhase 1
Imaging test for solid tumors using MNPR-101-DFO*-89Zr
This study tests whether a new imaging agent, MNPR-101-DFO*-89Zr, can find solid tumors and measure their uPAR levels. It might help doctors better understand your cancer and guide future treatment decisions.
North Melbourne, VictoriaAges 18 years+ - NCT06617169RecruitingPhase 1
Radioactive drug for solid tumors after prior study
This trial tests a new radioactive drug called MNPR-101-PCTA-177Lu for people with solid tumors who already completed a previous study (MNPR-101-D001). It aims to find the safest and most effective dose by carefully monitoring how your body handles the treatment.
North Melbourne, VictoriaAges 18 years+ - NCT06706700Recruiting
Biomarkers to predict cancer risk in pancreatic IPMN
This trial studies whether blood markers can help predict which pancreatic IPMNs are likely to become cancerous. If successful, it could help doctors decide when surgery is needed.
Milan, ItalyAges 18 years+ - NCT06792435RecruitingPhase 1/Phase 2
Study of XNW27011 for advanced solid tumors that failed standard therapy
This trial tests an investigational drug called XNW27011 for people with advanced solid tumors that have not responded to standard therapies. It may be especially relevant for tumors that have a specific protein called CLDN18.2, but it is not required for the first part of the study.
Jinan, ShandongAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
Denver, ColoradoAges 18 years+ - NCT03740256RecruitingPhase 1
HER2-targeted oncolytic virus plus custom immune cells for solid cancers
This Phase 1 study tests a treatment plan that combines a virus designed to attack cancer with your own custom immune cells that target HER2. It aims to shrink advanced HER2-positive solid tumors (and make future options safer/more effective).
Houston, TexasAges 18 years+
Hear when a new Pancreatic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic carcinoma?
- Yes. Clin2 currently lists 148 recruiting pancreatic carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.